Michael P Girouard1, Paul E Sax2, Robert A Parker3, Babafemi Taiwo4, Kenneth A Freedberg5, Roy M Gulick6, Milton C Weinstein7, A David Paltiel8, Rochelle P Walensky9. 1. Medical Practice Evaluation Center Division of General Internal Medicine, Massachusetts General Hospital. 2. Division of Infectious Diseases, Brigham and Women's Hospital Harvard Medical School. 3. Medical Practice Evaluation Center Harvard Medical School Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts. 4. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 5. Medical Practice Evaluation Center Division of General Internal Medicine, Massachusetts General Hospital Harvard Medical School Division of Infectious Diseases, Massachusetts General Hospital Department of Epidemiology, Boston University School of Public Health Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 6. Division of Infectious Diseases, Weill Medical College of Cornell University, New York, New York. 7. Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 8. Yale School of Public Health, New Haven, Connecticut. 9. Medical Practice Evaluation Center Division of General Internal Medicine, Massachusetts General Hospital Division of Infectious Diseases, Brigham and Women's Hospital Harvard Medical School Division of Infectious Diseases, Massachusetts General Hospital.
Abstract
BACKGROUND: Recommended human immunodeficiency virus (HIV) treatment regimens in the United States contain 3 antiretroviral agents, costing >$30 000/person/year. Pilot studies are evaluating the efficacy of dual therapy with dolutegravir (DTG) and lamivudine (3TC). We examined the potential cost-effectiveness and budget impact of DTG + 3TC regimens in the United States. METHODS: Using a mathematical model, we projected the clinical and economic outcomes of antiretroviral therapy (ART)-naive patients under 4 strategies: (1) no ART (for modeling comparison); (2) 2-drug: initial regimen of DTG + 3TC; (3) induction-maintenance: 48-week induction regimen of 3 drugs (DTG/abacavir [ABC]/3TC), followed by DTG + 3TC maintenance if virologically suppressed; and (4) standard of care: 3-drug regimen of DTG/ABC/3TC. Strategy-dependent model inputs, varied widely in sensitivity analyses, included 48-week virologic suppression (88%-93%), subsequent virologic failure (0.1%-0.6%/month), and Medicaid-discounted ART costs ($15 200-$39 600/year). A strategy was considered cost-effective if its incremental cost-effectiveness ratio (ICER) was <$100 000/quality-adjusted life-year (QALY). RESULTS: The 3 ART strategies had the same 5-year survival rates (90%). The ICER was $22 500/QALY for induction-maintenance and >$500 000/QALY for standard of care. Two-drug was the preferred strategy only when DTG + 3TC 48-week virologic suppression rate exceeded 90%. With 50% uptake of either induction-maintenance or 2-drug for ART-naive patients, cost savings totaled $550 million and $800 million, respectively, within 5 years; savings reached >$3 billion if 25% of currently suppressed patients were switched to DTG + 3TC maintenance. CONCLUSIONS: Should DTG + 3TC demonstrate high rates of virologic suppression, this regimen will be cost-effective and would save >$500 million in ART costs in the United States over 5 years.
BACKGROUND: Recommended human immunodeficiency virus (HIV) treatment regimens in the United States contain 3 antiretroviral agents, costing >$30 000/person/year. Pilot studies are evaluating the efficacy of dual therapy with dolutegravir (DTG) and lamivudine (3TC). We examined the potential cost-effectiveness and budget impact of DTG + 3TC regimens in the United States. METHODS: Using a mathematical model, we projected the clinical and economic outcomes of antiretroviral therapy (ART)-naive patients under 4 strategies: (1) no ART (for modeling comparison); (2) 2-drug: initial regimen of DTG + 3TC; (3) induction-maintenance: 48-week induction regimen of 3 drugs (DTG/abacavir [ABC]/3TC), followed by DTG + 3TC maintenance if virologically suppressed; and (4) standard of care: 3-drug regimen of DTG/ABC/3TC. Strategy-dependent model inputs, varied widely in sensitivity analyses, included 48-week virologic suppression (88%-93%), subsequent virologic failure (0.1%-0.6%/month), and Medicaid-discounted ART costs ($15 200-$39 600/year). A strategy was considered cost-effective if its incremental cost-effectiveness ratio (ICER) was <$100 000/quality-adjusted life-year (QALY). RESULTS: The 3 ART strategies had the same 5-year survival rates (90%). The ICER was $22 500/QALY for induction-maintenance and >$500 000/QALY for standard of care. Two-drug was the preferred strategy only when DTG + 3TC 48-week virologic suppression rate exceeded 90%. With 50% uptake of either induction-maintenance or 2-drug for ART-naive patients, cost savings totaled $550 million and $800 million, respectively, within 5 years; savings reached >$3 billion if 25% of currently suppressed patients were switched to DTG + 3TC maintenance. CONCLUSIONS: Should DTG + 3TC demonstrate high rates of virologic suppression, this regimen will be cost-effective and would save >$500 million in ART costs in the United States over 5 years.
Authors: José R Arribas; Pierre-Marie Girard; Roland Landman; Judit Pich; Josep Mallolas; María Martínez-Rebollar; Francisco X Zamora; Vicente Estrada; Manuel Crespo; Daniel Podzamczer; Joaquín Portilla; Fernando Dronda; José A Iribarren; Pere Domingo; Federico Pulido; Marta Montero; Hernando Knobel; André Cabié; Laurence Weiss; José M Gatell Journal: Lancet Infect Dis Date: 2015-06-07 Impact factor: 25.071
Authors: José A Perez-Molina; Rafael Rubio; Antonio Rivero; Juan Pasquau; Ignacio Suárez-Lozano; Melcior Riera; Miriam Estébanez; Jesús Santos; José Sanz-Moreno; Jesús Troya; Ana Mariño; Antonio Antela; Jordi Navarro; José Navarro; Herminia Esteban; Santiago Moreno Journal: Lancet Infect Dis Date: 2015-06-07 Impact factor: 25.071
Authors: K A Freedberg; E Losina; M C Weinstein; A D Paltiel; C J Cohen; G R Seage; D E Craven; H Zhang; A D Kimmel; S J Goldie Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: Sean D Sullivan; Josephine A Mauskopf; Federico Augustovski; J Jaime Caro; Karen M Lee; Mark Minchin; Ewa Orlewska; Pete Penna; Jose-Manuel Rodriguez Barrios; Wen-Yi Shau Journal: Value Health Date: 2013-12-13 Impact factor: 5.725
Authors: Eric L Ross; Milton C Weinstein; Bruce R Schackman; Paul E Sax; A David Paltiel; Rochelle P Walensky; Kenneth A Freedberg; Elena Losina Journal: Clin Infect Dis Date: 2015-01-12 Impact factor: 9.079
Authors: Pedro Cahn; Jaime Andrade-Villanueva; José R Arribas; José M Gatell; Javier R Lama; Michael Norton; Patricia Patterson; Juan Sierra Madero; Omar Sued; Maria Inés Figueroa; Maria José Rolon Journal: Lancet Infect Dis Date: 2014-04-27 Impact factor: 25.071
Authors: Jean B Nachega; Jean-Jacques Parienti; Olalekan A Uthman; Robert Gross; David W Dowdy; Paul E Sax; Joel E Gallant; Michael J Mugavero; Edward J Mills; Thomas P Giordano Journal: Clin Infect Dis Date: 2014-01-22 Impact factor: 9.079
Authors: François Raffi; Abdel G Babiker; Laura Richert; Jean-Michel Molina; Elizabeth C George; Andrea Antinori; Jose R Arribas; Jesper Grarup; Fleur Hudson; Christine Schwimmer; Juliette Saillard; Cédrick Wallet; Per O Jansson; Clotilde Allavena; Remko Van Leeuwen; Jean-François Delfraissy; Stefano Vella; Geneviève Chêne; Anton Pozniak Journal: Lancet Date: 2014-08-04 Impact factor: 79.321
Authors: Jason Gillman; Patrick Janulis; Roy Gulick; Carole L Wallis; Baiba Berzins; Roger Bedimo; Kimberly Smith; Michael Aboud; Babafemi Taiwo Journal: J Antimicrob Chemother Date: 2019-08-01 Impact factor: 5.790
Authors: Huldrych F Günthard; Michael S Saag; Constance A Benson; Carlos del Rio; Joseph J Eron; Joel E Gallant; Jennifer F Hoy; Michael J Mugavero; Paul E Sax; Melanie A Thompson; Rajesh T Gandhi; Raphael J Landovitz; Davey M Smith; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Babafemi O Taiwo; Vincent C Marconi; Baiba Berzins; Carlee B Moser; Amesika N Nyaku; Carl J Fichtenbaum; Constance A Benson; Timothy Wilkin; Susan L Koletar; Jonathan Colasanti; Edward P Acosta; Jonathan Z Li; Paul E Sax Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Babafemi O Taiwo; Lu Zheng; Andrei Stefanescu; Amesika Nyaku; Baiba Bezins; Carole L Wallis; Catherine Godfrey; Paul E Sax; Edward Acosta; David Haas; Kimberly Y Smith; Beverly Sha; Cornelius Van Dam; Roy M Gulick Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272